Study of Magrolimab in Patients With Solid Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Solid Tumor
Interventions
DRUG

Magrolimab

Administered intravenously

DRUG

Docetaxel

Administered intravenously

Trial Locations (49)

6189

Centre de Lutte Contre le Cancer (CLCC) - Centre Antoine Lacassagne (CAL) - Site Est, Nice

8003

Hospital del Mar, Barcelona

8023

Hospital Quironsalud Barcelona, Barcelona

8041

Hospital De La Santa Creu I Sant Pau, Barcelona

13005

Hopital Nord AP-HM, Marseille

21079

Centre Georges François Leclerc, Dijon

23007

Hospital Universitario de Jaen, Jaén

28007

Hospital General Universitario Gregorio Maranon, Madrid

28033

MD Anderson Cancer Center, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28050

Hospital HM Sanchinarro, Madrid

29010

Hospital Regional Universitario de Malaga, Málaga

29414

Charleston Oncology, Charleston

30265

Southeastern regional Medical Center, Newnan

30607

University Center and Blood Center,LLC., Athens

31008

Clinica Universidad de Navarra, Pamplona

32308

Tallahassee Memorial Healthcare Cancer Center, Tallahassee

33000

Institut Bergonie, Bordeaux

33064

University of Miami, Deerfield Beach

41009

Hospital Universitario Virgen Macarena, Seville

41013

Hospital Universitario Virgen del Rocio, Seville

46026

Hospital Universitari i Politecnic La Fe, Valencia

48109

University of Michigan, Ann Arbor

52242

University of Iowa Hospitals & Clinics, Iowa City

55102

Virginia Piper Cancer Center (Alliant Health), Saint Paul

59037

Centre Hospitalier Regional Universitaire de Lille, Lille

60077

Orchard Healthcare Research Inc, Skokie

69310

Centre Hospitalier Lyon-Sud, Pierre-Bénite

69373

Centre LÃon BÃrard Centre RÃgional de Lutte Contre Le Cancer, Lyon

75013

Hôpital de la Pitié Salpétrière, Paris

75230

Mary Crowley Cancer Research, Dallas

77030

MD Anderson Cancer Center, Dallas

83605

Saint Alphonsus Cancer Institute Caldwell, Caldwell

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

85338

Cancer Treatment Centers of America, Goodyear

89169

Comprehensive Cancer Centers of Nevada- Twain Office, Las Vegas

90404

Providence Saint John's Health Center, Santa Monica

92093

UC San Diego Moores Cancer Center, La Jolla

95403

St. Jude Hospital Yorba dba St. Joseph Heritage Healthcare, Santa Rosa

97239

Oregon Health & Science University, Portland

99208

Medical Oncology Associates,PS (dba Summit Cancer Center) (includes IP Shipment), Spokane

08816

Astera Cancer Care, East Brunswick

Unknown

Institut de Cancérologie de l'Ouest (ICO) - Saint-Herblain, Saint-Herblain

85-796

Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz

93-513

Instytut Centrum Zdrowia Matki Polki, Lodz

08-110

Wojewodzki Szpital Specjalistyczny w Siedlcach, Siedlce

08035

Instituto de Investigacion Oncologica Vall de Hebron, Barcelona

EC1A 7BE

Barts Health NHS Trust, London

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT04827576 - Study of Magrolimab in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter